Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer

Inclusion Criteria:

* Histologically confirmed metastatic adenocarcinoma of the lung
* Patients must have received and completed first line therapy
* Eastern Cooperative Oncology Group (ECOG) performance status of 0, or 1
* No external beam radiation therapy within 2 weeks of first vaccine administration
* No stereotactic radiation therapy within 3 days of first vaccine
* No targeted therapy within 2 weeks of first vaccine administration
* No immunomodulatory therapy within 2 weeks of first vaccine administration
* No chemotherapy within 4 weeks of first vaccine administration
* During Screening period, no steroid therapy within 4 weeks of first vaccine administration
* Patient's written informed consent
* Adequate organ function (measured within a week of beginning treatment):

  * White blood count (WBC) \> 3,000/mm³ and absolute neutrophil count (ANC) \>/= 1500/mm³
  * Platelets \> 100,000/mm³
  * Hematocrit \> 25%
  * Bilirubin \< 2.0 mg/dL
  * Creatinine \< 2.0 mg/dL, or creatinine clearance \> 60 mL/min
* Patients will be tested for HLA-A0201 as determined by flow cytometry followed by molecular analysis of a peripheral blood specimen; however this result will not be an inclusion criterion.
* Measurable metastatic tumor as defined by standard Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Lesions must be accurately measured in at least one dimension with the longest diameter ≥20 mm. With spiral computed tomography (CT) scan, lesion must be ≥10 mm in at least one dimension.

Exclusion Criteria:

* Symptomatic brain metastasis or Uncontrolled central nervous system (CNS) metastasis will not be permitted.
* Any acute medical problems requiring active intervention
* Current corticosteroid (other than replacement doses in patients who are hypo-adrenal) or other immunosuppressive therapy
* Any other pre-existing immunodeficiency condition (including known human immunodeficiency virus \[HIV\] infection)
* Any known pre-existing autoimmune disorder
* History of a second malignancy within the previous 2 years (except non-melanoma skin cancer and cervical in-situ)
* Patients who have had major surgery without full recovery or major surgery within three weeks of the start of vaccine treatment
* Pregnant or lactating women: Patients in reproductive age must agree to use contraceptive methods for the duration of the study (\*A pregnancy test will be obtained before treatment).
* Eastern Cooperative Oncology Group (ECOG) performance status of 2, 3, or 4
* Patients with other significant diseases or disorders that, in the Investigator's opinion, would exclude them from the study.
* Patients who at the discretion of the investigator are deemed to have rapidly progressive disease